CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,024,322 | -11.2% | 37,221 | +9.4% | 0.00% | 0.0% |
| Q2 2023 | $1,153,891 | -28.9% | 34,008 | -24.6% | 0.00% | 0.0% |
| Q1 2023 | $1,623,706 | +0.3% | 45,128 | +24.2% | 0.00% | 0.0% |
| Q4 2022 | $1,618,916 | +71.9% | 36,323 | +8.4% | 0.00% | 0.0% |
| Q3 2022 | $942,000 | -79.5% | 33,512 | -80.3% | 0.00% | -66.7% |
| Q2 2022 | $4,589,000 | +80.0% | 170,214 | +127.4% | 0.00% | +200.0% |
| Q1 2022 | $2,550,000 | -32.6% | 74,857 | -23.5% | 0.00% | -50.0% |
| Q4 2021 | $3,782,000 | +54.7% | 97,896 | +116.3% | 0.00% | +100.0% |
| Q3 2021 | $2,444,000 | +111.1% | 45,259 | +30.7% | 0.00% | 0.0% |
| Q2 2021 | $1,158,000 | +2216.0% | 34,631 | +1338.2% | 0.00% | – |
| Q1 2021 | $50,000 | -96.5% | 2,408 | -97.1% | 0.00% | -100.0% |
| Q4 2020 | $1,441,000 | -75.4% | 82,232 | -79.1% | 0.00% | -75.0% |
| Q3 2020 | $5,847,000 | – | 394,273 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |